Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664170 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
A Phase 1 study of Advanced Cancer, sponsored by Mast Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 13
- Study locations
NCT00664170 is a Phase 1 study of Advanced Cancer that has completed, run by Mast Therapeutics. The registered enrollment target is 39 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (84% lower). The trial reports 13 study locations across 7 states.
The verdict
NCT00664170, a Phase 1 study of Advanced Cancer, has completed, sponsored by Mast Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to compare an injectable emulsion form of docetaxel to Taxotere in patients with advanced cancer.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG ANX-514
Study Locations (13)
Other
- Marcelo T de Alvear - Buenos Aires
- Centro Oncologico de Integracion Regional - Mendoza
- Hospital Privado Santa Clara de Asis - Salta
- Centro Medico San Roque - San Miguel de Tucumán
- Isis Centro Especializado - Santa Fe
- Tallinn Cancer Clinic - Tallinn
- Tartu University Hospital, Clinic of Hematology and Oncology - Tartu
Alabama
- Northwest Alabama Cancer Center - Muscle Shoals
California
- UCSD Moores Cancer Center - La Jolla
Ohio
- Signal Point Hematology/Oncology Inc. - Middletown
Buenos Aires
- Hospital Universitario Austral - Buenos Aires
Santa Fe Province
- Centro Oncologico de Rosario - Rosario
Tucumán Province
- Hospital Regional de Concepcion - Concepción
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00664170
The ClinicalTrials.gov registry entry for NCT00664170 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Mast Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00664170 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00664170 about?
NCT00664170 is a clinical study titled "A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer". The purpose of this study is to compare an injectable emulsion form of docetaxel to Taxotere in patients with advanced cancer.
What is the current status of trial NCT00664170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2008-04. Estimated completion is 2009-04.
What conditions does trial NCT00664170 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00664170?
The interventions under investigation include: docetaxel (DRUG), ANX-514 (DRUG).
Who is sponsoring clinical trial NCT00664170?
This trial is sponsored by Mast Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00664170 being conducted?
This trial has 13 study locations across Alabama, California, Ohio, Buenos Aires, Santa Fe Province. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.